drugset / Trial / NCT02410239
MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).
Timeline
- Start
- 2015-06
- Primary completion
- 2017-07
- Completion
- 2022-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mesenchymal stem cells | Cell therapy | 2.5e+06 cells/kg | Intrathecal |
| Subject | mesenchymal stem cells | Cell therapy | 5e+06 cells/kg | Intrathecal |
| Subject | mesenchymal stem cells | Cell therapy | 7.5e+06 cells/kg | Intrathecal |